risedronic acid and Bone Loss, Osteoclastic studies

Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.

Research Excerpts

Excerpt	Relevance	Reference
"Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures."	9.30	Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019)
"The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis."	9.11	Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004)
"The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)."	7.78	Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012)
"Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures."	5.30	Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. ( Blake, GM; Coleman, RE; Cuzick, J; Eastell, R; Patel, R; Sestak, I, 2019)
"The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia."	5.14	Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. ( Stepan, JJ; Zikan, V, 2009)
"The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis."	5.11	Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004)
" The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates."	4.79	Bisphosphonate therapy. ( Licata, AA, 1997)
" aestivum (200 and 400 mg/kg/day, po, for 30 days) and risedronate (20 microg/kg, sc, five times a week for 30 days) following methyl prednisolone sodium succinate (10 mg/kg, sc, thrice a week for 4 weeks) induced osteoporosis in Wistar rats showed an increase in the serum levels of bone mineral content markers, decrease in the serum and urinary levels of bone resorption markers."	3.80	Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats. ( Abbagoni, S; Banji, D; Banji, OJ; Chiluka, VL, 2014)
"The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)."	3.78	Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012)
"3-(3-Pyridyl)-2-hydroxy-2-phosphonopropanoic acid (3-PEHPC, 1) is a phosphonocarboxylate (PC) analogue of 2-(3-pyridyl)-1-hydroxyethylidenebis(phosphonic acid) (risedronic acid, 2), an osteoporosis drug that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, preventing protein prenylation."	3.76	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. ( Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA, 2010)
"These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw."	3.76	Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010)
"Secondary outcomes included changes in bone resorption (betaCTX) and 12-month changes in BMD."	2.75	Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. ( Keel, C; Kraenzlin, CA; Kraenzlin, ME; Meier, C; Müller, B, 2010)
" Despite serum isoflavone profiles indicating bioavailability of the phytoestrogens, only soy isoflavones from the cotyledon and germ significantly decreased net bone resorption by 9% (P = 0."	2.74	Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. ( Barnes, S; Boris, ME; Jackson, GS; Martin, BR; McCabe, GP; McCabe, LD; Nolan, JR; Peacock, M; Reinwald, S; Weaver, CM, 2009)
"Alendronate was randomly prescribed for 41 patients and risedronate were prescribed for 43 patients."	2.73	Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. ( Iizuka, T; Matsukawa, M, 2008)
"Urinary deoxypyridinoline, a bone resorption marker, decreased by 46."	2.73	Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. ( Honda, Y; Iwamoto, J; Sato, Y, 2007)
"The effect of risedronate treatment on bone resorption was investigated quantitatively by measuring N-telopeptide levels in urine of patients with hip fracture."	2.73	[The effect of risedronate treatment on bone turnover markers in patients with hip fracture]. ( Altintaş, F; Beyzadeoğlu, T; Eren, A; Güven, M; Ozkut, AT, 2007)
"Proximal bone resorption around the femoral stem often has been observed after total hip arthroplasty (THA), could lead to late stem loosening."	2.73	Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. ( Fuji, T; Masuhara, K; Nakai, T; Seino, Y; Yamaguchi, K; Yamasaki, S, 2007)
"One of the most widely used bone resorption markers is cross-linked N-terminal telopeptides (NTX)."	2.73	Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. ( Abe, Y; Fukao, A; Ishikawa, H, 2008)
"There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients."	2.72	Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. ( Ando, K; Higashi, M; Kanaji, A; Namisato, M; Nishio, M; Yamada, H, 2006)
"To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis."	2.71	Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. ( Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L, 2003)
"Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal."	2.71	Monitoring of Risedronate by biochemical bone markers in clinical practice. ( Bunyaratavej, N, 2005)
"Greater decreases in bone resorption markers were associated with greater decreases in vertebral (and nonvertebral) fractures."	2.71	Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. ( Barton, I; Chines, A; Delmas, PD; Eastell, R; Garnero, P; Hannon, RA, 2003)
"Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts."	2.45	[Risedronate for treatment of osteoporosis]. ( Hagino, H, 2009)
" Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis."	2.43	Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2005)
" Although newer bisphosphonates are more potent, oral bioavailability remains < 1%."	2.41	Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)
"The frequency distribution of the bone resorption marker urinary deoxypyridinoline crosslinks (uDPD), was obtained retrospectively from 211 osteoporotic women attended at an academic hospital endocrine clinic, treated for >2 years with oral bisphosphonates."	1.46	BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD. ( Liel, Y; Plakht, Y; Tailakh, MA, 2017)
"We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13."	1.35	Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009)
"Untreated minipigs displayed a deep bone resorption pit, beneath the graft region, filled with type I collagen tissue as determined through immunohistochemical staining."	1.35	Effect of risedronate in a minipig cartilage defect model with allograft. ( Abe, Y; Li, J; Masuda, K; Muehleman, C; Pfister, B; Phipps, R; Sah, RL, 2009)
"Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production."	1.35	Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008)
"Risedronate decreased bone cancer-related bone destruction and pain-related behavior and decreased the spinal expression of glial fibrillary acidic protein, whereas NE-10790 had no effect on these parameters."	1.35	Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. ( Croucher, PI; Ding, M; Ebetino, FH; Gallagher, O; Hald, A; Hansen, RR; Heegaard, AM; Kassem, M; Thomsen, MW, 2009)
" In two groups, anterior cruciate ligament transection was performed and half were left untreated, and the other half dosed with risedronate (0."	1.35	Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. ( Boyd, SK; Doschak, MR; MacNeil, JA; Zernicke, RF, 2008)
"Osteoporosis is a severe complication of glucocorticoid treatment."	1.34	Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. ( Bertoldo, F; Dalle Carbonare, L; Fassina, A; Giannini, S; Lo Cascio, V; Realdi, G; Sella, S; Turco, G; Valenti, MT; Zordan, S, 2007)
"We studied the bone resorption state in GC-treated CKD patients and the effects of bisphosphonate on S-NTX."	1.33	Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. ( Fujii, N; Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Moriyama, T; Nagasawa, Y; Okada, N, 2006)
"The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis."	1.33	Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006)
" The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat."	1.31	Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. ( Hunziker, J; Miller, SC; Wronski, TJ, 2000)
" We found, in dose-response studies, that alendronate and risedronate inhibit bone resorption (in pit assays) at doses tenfold lower than those reducing osteoclast number."	1.31	Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. ( Halasy-Nagy, JM; Reszka, AA; Rodan, GA, 2001)
"These data suggest that the anti-bone resorption activities of TRK-530 are possibly unrelated to its antioxidant properties."	1.30	TRK-530 inhibits accumulation of superoxide anions derived from human polymorphonuclear leukocytes and bone resorption induced by activated osteoclasts. ( Funaba, Y; Kawabe, N; Nakadate-Matsushita, T; Tanahashi, M; Tateishi, A, 1998)
"Human breast cancer frequently metastasizes to the skeleton to cause osteolysis and subsequent pain, pathological fracture, and hypercalcemia."	1.29	Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. ( Boyce, BF; Boyce, R; Chapman, M; Mundy, GR; Sasaki, A; Story, B; Wright, KR; Yoneda, T, 1995)
"It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroidectomized rats at a SC dose as low as 0."	1.28	BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. ( Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K, 1991)

Research

Studies (120)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Change in Bone Mineral Density (BMD) at the Spine (L1-L4) Based on Randomization to Control, Risedronate, or Exercise Group.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	24 (20.00)	18.2507
2000's	65 (54.17)	29.6817
2010's	27 (22.50)	24.3611
2020's	4 (3.33)	2.80

Authors	Studies
Szajnman, SH	1
Bailey, BN	1
Docampo, R	1
Rodriguez, JB	1
Szabo, CM	2
Matsumura, Y	1
Fukura, S	1
Martin, MB	2
Sanders, JM	2
Sengupta, S	1
Cieslak, JA	1
Loftus, TC	1
Lea, CR	1
Lee, HJ	1
Koohang, A	1
Coates, RM	1
Sagami, H	1
Oldfield, E	3
Song, Y	1
Chan, JM	1
Zhang, Y	3
Jennings, S	1
Kosztowski, T	1
Odeh, S	1
Flessner, R	1
Schwerdtfeger, C	1
Kotsikorou, E	1
Meints, GA	1
Gómez, AO	1
González-Pacanowska, D	1
Raker, AM	1
Wang, H	1
van Beek, ER	2
Papapoulos, SE	2
Morita, CT	1
Abdou, WM	1
Ganoub, NA	1
Geronikaki, A	1
Sabry, E	1
McKenna, CE	1
Kashemirov, BA	1
Błazewska, KM	1
Mallard-Favier, I	1
Stewart, CA	1
Rojas, J	1
Lundy, MW	1
Ebetino, FH	5
Baron, RA	1
Dunford, JE	1
Kirsten, ML	1
Seabra, MC	1
Bala, JL	1
Marma, MS	1
Rogers, MJ	3
Coxon, FP	3
Huang, K	1
Wang, G	1
Zeng, Y	1
Nakura, N	2
Hirakawa, K	2
Takayanagi, S	2
Mihara, M	2
Mori, Y	1
Mori, N	1
Liel, Y	1
Plakht, Y	1
Tailakh, MA	1
Forte, L	1
Sarda, S	1
Combes, C	1
Brouillet, F	1
Gazzano, M	1
Marsan, O	1
Boanini, E	1
Bigi, A	1
Ye, T	1
Cao, P	1
Qi, J	1
Zhou, Q	1
Rao, DS	1
Qiu, S	1
Wang, M	1
Wang, L	1
Ye, R	1
Yang, L	1
Li, Q	1
Xu, B	1
Sestak, I	1
Blake, GM	1
Patel, R	1
Coleman, RE	1
Cuzick, J	1
Eastell, R	3
Thomsen, JS	3
Straarup, TS	1
Danielsen, CC	2
Oxlund, H	2
Brüel, A	1
Matheny, JB	1
Slyfield, CR	1
Tkachenko, EV	1
Lin, I	1
Ehlert, KM	1
Tomlinson, RE	1
Wilson, DL	1
Hernandez, CJ	1
Kikuta, J	1
Ishii, M	1
Banji, D	1
Banji, OJ	1
Chiluka, VL	1
Abbagoni, S	1
Muren, O	1
Akbarian, E	1
Salemyr, M	1
Bodén, H	1
Eisler, T	1
Stark, A	1
Sköldenberg, O	1
Yuan, H	1
Niu, LN	1
Jiao, K	1
Pei, DD	1
Pramanik, C	1
Li, JY	1
Messer, R	1
Kumar, S	1
Pashley, DH	1
Tay, FR	1
Gong, T	1
Chen, Y	2
Liu, X	2
Troczynski, T	1
Häfeli, UO	1
Iwamoto, J	6
Matsumoto, H	1
Takeda, T	5
Sato, Y	6
Yeh, JK	5
Adami, S	2
Giannini, S	2
Bianchi, G	1
Sinigaglia, L	1
Di Munno, O	1
Fiore, CE	1
Minisola, S	1
Rossini, M	1
Iizuka, T	1
Matsukawa, M	1
Muehleman, C	1
Li, J	2
Abe, Y	2
Pfister, B	1
Sah, RL	1
Phipps, R	1
Masuda, K	1
Zikan, V	1
Stepan, JJ	1
Brookler, K	1
Izumi, K	1
Mizokami, A	1
Sugimoto, K	1
Narimoto, K	1
Miwa, S	1
Maeda, Y	1
Kadono, Y	2
Takashima, M	1
Koh, E	1
Namiki, M	1
Hagino, H	1
Hald, A	1
Hansen, RR	1
Thomsen, MW	1
Ding, M	1
Croucher, PI	1
Gallagher, O	1
Kassem, M	1
Heegaard, AM	1
Kwak, HB	1
Kim, JY	1
Kim, KJ	1
Choi, MK	1
Kim, JJ	1
Kim, KM	1
Shin, YI	1
Lee, MS	1
Kim, HS	1
Kim, JW	1
Chun, CH	1
Cho, HJ	1
Hong, GY	1
Juhng, SK	1
Yoon, KH	1
Park, BH	1
Bae, JM	1
Han, JK	1
Oh, J	1
Weaver, CM	1
Martin, BR	1
Jackson, GS	1
McCabe, GP	1
Nolan, JR	1
McCabe, LD	1
Barnes, S	1
Reinwald, S	1
Boris, ME	1
Peacock, M	1
Keel, C	1
Kraenzlin, ME	1
Kraenzlin, CA	1
Müller, B	1
Meier, C	1
Allen, MR	1
Erickson, AM	1
Wang, X	1
Burr, DB	2
Martin, RB	1
Hazelwood, SJ	1
Ohtori, S	1
Akazawa, T	1
Murata, Y	1
Kinoshita, T	1
Yamashita, M	1
Nakagawa, K	1
Inoue, G	1
Nakamura, J	1
Orita, S	1
Ochiai, N	1
Kishida, S	1
Takaso, M	1
Eguchi, Y	1
Yamauchi, K	1
Suzuki, M	1
Aoki, Y	1
Takahashi, K	1
Oizumi, T	1
Funayama, H	1
Yamaguchi, K	2
Yokoyama, M	1
Takahashi, H	1
Yamamoto, M	1
Kuroishi, T	1
Kumamoto, H	1
Sasaki, K	1
Kawamura, H	1
Sugawara, S	1
Endo, Y	1
Aspenberg, P	1
Schilcher, J	1
Fahlgren, A	1
Fournier, PG	1
Stresing, V	1
Clézardin, P	1
Heidari, P	1
Abbaspour, A	1
Baghdadi, T	1
Espandar, R	1
Farzan, M	1
Amanpour, S	1
Rasouli, MR	1
Mohagheghi, MA	1
Amiri, HR	1
Yasui, N	1
Winzenberg, T	1
Jones, G	1
Miller, KK	1
Meenaghan, E	1
Lawson, EA	1
Misra, M	1
Gleysteen, S	1
Schoenfeld, D	1
Herzog, D	1
Klibanski, A	1
Matsumoto, T	1
Nagase, Y	1
Iwasawa, M	1
Yasui, T	1
Masuda, H	1
Nakamura, K	1
Tanaka, S	1
Sköldenberg, OG	1
Salemyr, MO	1
Bodén, HS	1
Ahl, TE	1
Adolphson, PY	1
Sergi, G	1
Pintore, G	1
Falci, C	1
Veronese, N	1
Berton, L	1
Perissinotto, E	1
Basso, U	1
Brunello, A	1
Monfardini, S	1
Manzato, E	1
Coin, A	1
Eriksen, EF	3
Melsen, F	1
Sod, E	1
Barton, I	3
Chines, A	2
Takami, M	1
Suda, K	1
Sahara, T	1
Itoh, K	1
Nagai, K	1
Sasaki, T	1
Udagawa, N	2
Takahashi, N	2
Hannon, RA	2
Garnero, P	3
Delmas, PD	3
Hosking, D	2
Felsenberg, D	1
Andia, JC	1
Välimäki, M	1
Benhamou, L	1
Reginster, JY	1
Yacik, C	1
Rybak-Feglin, A	1
Petruschke, RA	1
Zaru, L	1
Santora, AC	1
Nakamura, M	1
Matsuura, S	1
Mogi, M	1
Nakamura, H	1
Horiuchi, H	1
Saito, N	1
Hiraoka, BY	1
Kobayashi, Y	1
Takaoka, K	1
Ozawa, H	1
Miyazawa, H	1
Callaci, JJ	1
Juknelis, D	1
Patwardhan, A	1
Sartori, M	1
Frost, N	1
Wezeman, FH	1
Seibel, MJ	1
Naganathan, V	1
Grauer, A	1
Kishimoto, H	1
Li, CY	1
Price, C	1
Delisser, K	1
Nasser, P	1
Laudier, D	1
Clement, M	1
Jepsen, KJ	1
Schaffler, MB	1
Sebba, AI	1
Bonnick, SL	1
Kagan, R	1
Thompson, DE	1
Skalky, CS	1
Chen, E	1
de Papp, AE	1
Pande, I	1
Hosking, DJ	3
Maricic, M	1
Rackoff, PJ	1
Sebba, A	1
Suzuki, K	1
Takeyama, S	1
Kikuchi, T	1
Yamada, S	1
Sodek, J	1
Shinoda, H	1
Heaney, RP	1
Valent, DJ	1
Barton, IP	1
Takada, J	1
Seki, A	3
Yamada, H	4
Shen, CL	3
Hamano, T	2
Fujii, N	2
Nagasawa, Y	2
Isaka, Y	2
Moriyama, T	2
Okada, N	1
Imai, E	2
Horio, M	2
Ito, T	2
Iwata, K	1
Follet, H	1
Phipps, RJ	1
Kanaji, A	1
Higashi, M	1
Namisato, M	1
Nishio, M	1
Ando, K	1
Mikami, S	1
Hori, M	1
Honda, Y	1
Altintaş, F	1
Ozkut, AT	1
Beyzadeoğlu, T	1
Eren, A	1
Güven, M	1
Bunyaratavej, N	1
Yamasaki, S	1
Masuhara, K	1
Nakai, T	1
Fuji, T	1
Seino, Y	1
Campbell, MJ	1
Aronstein, WS	1
Cohen, SB	1
Conaghan, PG	1
Cline, GA	1
Christiansen, C	1
Beary, JF	1
Meyer, JM	1
Bingham, CO	1
Dalle Carbonare, L	1
Bertoldo, F	1
Valenti, MT	1
Zordan, S	1
Sella, S	1
Fassina, A	1
Turco, G	1
Realdi, G	1
Lo Cascio, V	1
MacNeil, JA	1
Doschak, MR	1
Zernicke, RF	1
Boyd, SK	1
Cesareo, R	1
Iozzino, M	1
Alva, D	1
Napolitano, C	1
De Rosa, B	1
Contini, S	1
Mallardo, L	1
Lauria, A	1
Reda, G	1
Orsini, A	1
Ishikawa, H	1
Fukao, A	1
Thompson, K	1
Roelofs, AJ	1
Dane, C	1
Dane, B	1
Cetin, A	1
Erginbas, M	1
Jee, WS	3
Lin, BY	1
Ma, YF	1
Ke, HZ	3
Sasaki, A	1
Boyce, BF	1
Story, B	1
Wright, KR	1
Chapman, M	1
Boyce, R	1
Mundy, GR	2
Yoneda, T	1
Li, M	1
Mosekilde, L	3
Søgaard, CH	2
Wronski, TJ	6
Boyce, RW	2
Paddock, CL	2
Gleason, JR	1
Sletsema, WK	1
Ebert, DC	1
Stevens, ML	1
Youngs, TA	1
Gundersen, HJ	1
McOsker, JE	1
Baumann, BD	1
Hall, DG	1
Stoica, G	1
Reasner, CA	1
Stone, MD	1
Ballah, A	1
Ma, Y	1
Gasser, J	1
Li, XJ	1
Kimmel, DB	2
Licata, AA	1
Tanahashi, M	1
Funaba, Y	1
Tateishi, A	1
Kawabe, N	1
Nakadate-Matsushita, T	1
Luckman, SP	1
Hughes, DE	1
Graham, R	1
Russell, G	1
Ejersted, C	1
Andreassen, TT	1
Goa, KL	1
Balfour, JA	1
Peter, CP	1
Handt, LK	1
Smith, SM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of Video-Assisted Discharge Education After Total Hip Replacement Surgery on Activities of Daily Living, Functionality and Patient Satisfaction: A Randomized Controlled Study[NCT04774562]		31 participants (Actual)	Interventional	2018-09-04	Completed
The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology[NCT02367846]	Phase 4	6 participants (Actual)	Interventional	2015-01-31	Active, not recruiting
Berries and Bones: The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover[NCT02630797]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2017-01-12	Active, not recruiting
A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014]	Phase 3	1,053 participants (Actual)	Interventional	2002-09-01	Completed
Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600]	Phase 3	276 participants (Actual)	Interventional	2015-02-01	Completed
Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203]	Phase 2	120 participants (Actual)	Interventional	2002-10-31	Completed
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial[NCT01400516]	Phase 4	26 participants (Actual)	Interventional	2011-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months

Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group.

Intervention	g/cm^2 (Mean)
	Baseline	6 Months	12 Months
Control	0.889	.887	0.885
Exercise	0.886	.878	0.885
Risedronate	0.892	.907	0.911

"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months

Change in Serum Measures of Bone Resorption (Serum NTx) Based on Randomization to Control, Risedronate, or Exercise Group.

Intervention	mg^2/mm^4 (Mean)
	Baseline	6 Months	12 Months
Control	2098.7	2105.89	2107.2
Exercise	2001	1987.42	2009.2
Risedronate	1993.3	1997.32	2014.2

Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months

Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) and Instant Vertebral Assessment (IVA) Scan

Intervention	nanoMolar Bone Collagen Equivalents/L (Mean)
	Baseline	6 Months	12 Months
Control	13.99	12.16	12.36
Exercise	15.03	13.36	13.92
Risedronate	14.31	10.30	11.42

BMD was measured at the lumbosacral spine antero-posterior and at the femoral neck using a densitometer. A positive change from Baseline (increased bone density) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Change From Baseline in Disease Activity Score 28 Joint Count C-Reactive Protein (DAS-28 CRP)

Intervention	grams/centimeters squared (g/cm^2) (Mean)
	Spine, Baseline	Spine, Change from Baseline at Month12	Femoral neck, Baseline	Femoral neck, Change from Baseline at Month 12
Control Arm	0.93	-0.002	0.73	-0.03
Teriparatide	0.91	0.06	0.68	0.03

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Change From Baseline in Joint Erosion Volume Measured by 3-Dimensional Computed Tomography (3D CT) Scan

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 12
Control Arm	2.73	-0.50
Teriparatide	2.66	0.42

Both hands were scanned using a CT scanner. A semi-automated software tool was used to segment the erosion margins in 3D. A board certified radiologist identified the individual erosions in six sub-regions: radius, ulna, proximal carpals, distal carpals, metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints. The average total in a single hand/wrist was calculated. A negative change from Baseline(less joint erosions) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Article	Year
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty: A systematic review and meta-analysis. International journal of surgery (London, England), 2018, Volume: 52 Topics: Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Hum	2018
The efficiency of risedronate in reducing bone resorption after total hip arthroplasty: a meta-analysis of randomized control trials at a minimum of 6 months' follow-up. Journal of orthopaedic surgery and research, 2018, Apr-17, Volume: 13, Issue:1 Topics: Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Fol	2018
Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis. Journal of orthopaedic surgery and research, 2018, Jun-07, Volume: 13, Issue:1 Topics: Adult; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorpti	2018
[Dynamics of bone resorption analyzed by intravital imaging]. Clinical calcium, 2013, Volume: 23, Issue:11 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal;	2013
[Risedronate for treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5 Topics: Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Fractures, Bone; Fractures, Spont	2009
[Risedronate treatment for osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Back Pain; Bone Density; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fra	2004
Oral antiresorptive therapy. Current rheumatology reports, 2005, Volume: 7, Issue:1 Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, C	2005
Glucocorticoid-induced osteoporosis: treatment options and guidelines. Current osteoporosis reports, 2005, Volume: 3, Issue:1 Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractu	2005
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. Treatments in endocrinology, 2005, Volume: 4, Issue:4 Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans;	2005
Pharmacological therapy of Paget's and other metabolic bone diseases. Bone, 2006, Volume: 38, Issue:2 Suppl 2 Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Etidron	2006
[Application of anti-resorptive drugs for the treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:2 Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans;	2006
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures. Minerva endocrinologica, 2007, Volume: 32, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosph	2007
Bisphosphonate therapy. The American journal of the medical sciences, 1997, Volume: 313, Issue:1 Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid;	1997
Risedronate. Drugs & aging, 1998, Volume: 13, Issue:1 Topics: Animals; Biological Availability; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resor	1998
Prediction and assessment of the response of Paget's disease to bisphosphonate treatment. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Alkaline Phosphatase; Bone Resorption; Diphosphonates; Etidronic Acid; Half-Life; Humans; Osteitis D	1999
The use of risedronate in Paget's disease. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Fibrous Dysplasia,	1999
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm	2000
Risedronate: clinical usage. International journal of clinical practice, 2001, Volume: 55, Issue:4 Topics: Bone Density; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Ostei	2001

Article	Year
Denosumab prevented periprosthetic bone resorption better than risedronate after total hip arthroplasty. Journal of bone and mineral metabolism, 2023, Volume: 41, Issue:2 Topics: Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Den	2023
Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone, 2019, Volume: 124 Topics: Anastrozole; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Female; Frac	2019
No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial. Acta orthopaedica, 2015, Volume: 86, Issue:5 Topics: Absorptiometry, Photon; Adult; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Cons	2015
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. Climacteric : the journal of the International Menopause Society, 2008, Volume: 11, Issue:4 Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bo	2008
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. Bone, 2009, Volume: 44, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents	2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi	2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi	2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi	2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi	2009
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. Journal of bone and mineral metabolism, 2010, Volume: 28, Issue:1 Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents;	2010
Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:2 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation	2010
Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:7 Topics: Administration, Cutaneous; Adult; Androgens; Anorexia Nervosa; Bone Density; Bone Density Conservati	2011
The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. The Journal of bone and joint surgery. American volume, 2011, Oct-19, Volume: 93, Issue:20 Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Analysis of Variance; Arthroplasty, Repla	2011
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone, 2002, Volume: 31, Issue:5 Topics: Aged; Aged, 80 and over; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Humans; Middle Ag	2002
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2003, Volume: 18, Issue:6 Topics: Aged; Biomarkers; Bone Resorption; Calcium Channel Blockers; Collagen; Collagen Type I; Etidronic Ac	2003
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Current medical research and opinion, 2003, Volume: 19, Issue:5 Topics: Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Calcium C	2003
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:2 Topics: Aged; Amino Acids; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Incidence; Osteopo	2004
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Current medical research and opinion, 2004, Volume: 20, Issue:12 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Calcium Channel Blockers; Do	2004
Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. Leprosy review, 2006, Volume: 77, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Bli	2006
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:6 Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Drug Therapy, Combination	2007
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology, 2007, Mar-20, Volume: 68, Issue:12 Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo	2007
[The effect of risedronate treatment on bone turnover markers in patients with hip fracture]. Acta orthopaedica et traumatologica turcica, 2007, Volume: 41, Issue:2 Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collage	2007
Monitoring of Risedronate by biochemical bone markers in clinical practice. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:suppl 5 Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bo	2005
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007, Volume: 18, Issue:7 Topics: Absorptiometry, Photon; Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bo	2007
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis and cartilage, 2008, Volume: 16, Issue:6 Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Cartilage, Articular; Collagen	2008
Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. The Tohoku journal of experimental medicine, 2008, Volume: 214, Issue:1 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Meth	2008
Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2008, Volume: 24, Issue:4 Topics: Aged; Algorithms; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resor	2008
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and rheumatism, 1999, Volume: 42, Issue:11 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Analysis of Variance; Biomarker	1999
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcified tissue international, 2002, Volume: 71, Issue:2 Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Calcium Channel Blockers; Dos	2002

Article	Year
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi. Bioorganic & medicinal chemistry letters, 2001, Mar-26, Volume: 11, Issue:6 Topics: Animals; Bone Resorption; Diphosphonates; Fatty Acids; Humans; Inhibitory Concentration 50; Parasiti	2001
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. Journal of medicinal chemistry, 2002, May-23, Volume: 45, Issue:11 Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitor	2002
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphos	2002
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Dictyostelium	2005
Synthesis, properties, and perspectives of gem-diphosphono substituted-thiazoles. European journal of medicinal chemistry, 2008, Volume: 43, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Bone Resorption;	2008
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Surv	2010
Letter to the Editor: Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis. Journal of orthopaedic surgery and research, 2022, 01-05, Volume: 17, Issue:1 Topics: Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Hum	2022
Approaches to reduce periprosthetic bone resorption after total hip arthroplasty. Journal of bone and mineral metabolism, 2023, Volume: 41, Issue:4 Topics: Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Hum	2023
Response to letter to the editor on "Approach to reduce periprosthetic bone resorption after total hip arthroplasty". Journal of bone and mineral metabolism, 2023, Volume: 41, Issue:4 Topics: Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Resorption; Humans; Risedroni	2023
BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND "DRUG HOLIDAY" IN THE REAL WORLD. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:7 Topics: Administration, Intravenous; Administration, Oral; Aged; Alendronate; Amino Acids; Bone Density Cons	2017
Hydroxyapatite functionalization to trigger adsorption and release of risedronate. Colloids and surfaces. B, Biointerfaces, 2017, Dec-01, Volume: 160 Topics: Adsorption; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Delayed-Acti	2017
Protective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats. PloS one, 2017, Volume: 12, Issue:10 Topics: Animals; Apoptosis; Bone Resorption; Cancellous Bone; Dose-Response Relationship, Drug; Female; Oste	2017
No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis. Scandinavian journal of rheumatology, 2013, Volume: 42, Issue:5 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Cartilage, A	2013
Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study. Bone, 2013, Volume: 57, Issue:1 Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Etidronic Acid; Female;	2013
Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats. Indian journal of experimental biology, 2014, Volume: 52, Issue:2 Topics: Animals; Bone Density; Bone Resorption; Collagen; Etidronic Acid; Femur; Free Radical Scavengers; Gl	2014
Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass. Acta biomaterialia, 2016, Volume: 31 Topics: Animals; Apoptosis; Bone Resorption; Borates; Cell Differentiation; Diphosphonates; Glass; Imidazole	2016
Osteogenic and anti-osteoporotic effects of risedronate-added calcium phosphate silicate cement. Biomedical materials (Bristol, England), 2016, 07-07, Volume: 11, Issue:4 Topics: Animals; Bone Cements; Bone Density Conservation Agents; Bone Resorption; Calcium Phosphates; Female	2016
Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcified tissue international, 2008, Volume: 83, Issue:2 Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Dru	2008
Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A	2009
Effect of risedronate in a minipig cartilage defect model with allograft. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2009, Volume: 27, Issue:3 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cartilage, Articular; Chondrocytes; Coll	2009
Medical treatment of otosclerosis: rationale for use of bisphosphonates. The international tinnitus journal, 2008, Volume: 14, Issue:2 Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined	2008
Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology, 2009, Volume: 73, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density Conservation Agents; Bone Resorption; Et	2009
Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. International journal of cancer, 2009, Sep-01, Volume: 125, Issue:5 Topics: Acid Phosphatase; Animals; Behavior, Animal; Bone Density Conservation Agents; Bone Neoplasms; Bone	2009
Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:7 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Line; Cell Su	2009
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcified tissue international, 2010, Volume: 86, Issue:1 Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cell Aggreg	2010
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:5 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern	2010
Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack. Acta orthopaedica, 2010, Volume: 81, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Bone Nails; Bone Resorption; Etidronic Acid; Female;	2010
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:7 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell L	2010
Effect of risedronate on bone resorption during consolidation phase of distraction osteogenesis: a rabbit model. Journal of orthopaedic surgery (Hong Kong), 2010, Volume: 18, Issue:2 Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Bone Resorption; Disease Models, Anima	2010
When do bisphosphonates make the most sense? The Journal of family practice, 2011, Volume: 60, Issue:1 Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Re	2011
Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis and rheumatism, 2011, Volume: 63, Issue:12 Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Density; Bone Density	2011
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:4 Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De	2012
Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts. Bone, 2003, Volume: 32, Issue:4 Topics: Actins; Animals; Bone Resorption; Cells, Cultured; Diphosphonates; Enzyme Inhibitors; Etidronic Acid	2003
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology, 2003, Volume: 144, Issue:12 Topics: Animals; Bone and Bones; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Resorption;	2003
The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment. Alcoholism, clinical and experimental research, 2004, Volume: 28, Issue:1 Topics: Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Diphosphonates; Ethano	2004
Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:1 Topics: Animals; Bone Resorption; Calcium Channel Blockers; Diphosphonates; Dogs; Drug Resistance; Etidronic	2005
[To increase bone density faster and stronger]. MMW Fortschritte der Medizin, 2005, May-05, Volume: 147, Issue:18 Topics: Alendronate; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Multicenter	2005
Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2005, Volume: 53, Issue:12 Topics: Acid Phosphatase; Actins; Alkaline Phosphatase; Animals; Animals, Newborn; Bone Density; Bone Resorp	2005
Hospitalization-related bone loss and the protective effect of risedronate. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:2 Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Female; Femur	2006
Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia. Journal of nutritional science and vitaminology, 2006, Volume: 52, Issue:1 Topics: Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metaboli	2006
Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. Bone, 2006, Volume: 39, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Bone Density; Bone Density	2006
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone, 2006, Volume: 39, Issue:5 Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorpti	2006
Preventive effects of risedronate and calcitriol on cancellous osteopenia in rats treated with high-dose glucocorticoid. Experimental animals, 2006, Volume: 55, Issue:4 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption	2006
Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. Experimental animals, 2006, Volume: 55, Issue:5 Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Meta	2006
Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats: a comparison with the effects of alfacalcidol. Journal of nutritional science and vitaminology, 2006, Volume: 52, Issue:6 Topics: Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Res	2006
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2007, Volume: 22, Issue:11 Topics: Access to Information; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic;	2007
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. Journal of endocrinological investigation, 2007, Volume: 30, Issue:9 Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Mo	2007
Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. Clinical biomechanics (Bristol, Avon), 2008, Volume: 23, Issue:3 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Computer Simulation; Disease Models, Ani	2008
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone, 2008, Volume: 42, Issue:5 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Line, Tumor; Cell Surv	2008
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:6 Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channe	1995
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer research, 1995, Aug-15, Volume: 55, Issue:16 Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cachexia; Diphosphonates; Etidronic Acid	1995
Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone, 1995, Volume: 16, Issue:6 Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitoni	1995
The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:2 Topics: Administration, Oral; Animals; Bone Density; Bone Development; Bone Diseases, Metabolic; Bone Remode	1995
Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone, 1995, Volume: 16, Issue:2 Topics: Animals; Bone Resorption; Calcium Channel Blockers; Disease Models, Animal; Estradiol; Etidronic Aci	1995
The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model. Bone, 1995, Volume: 16, Issue:2 Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone	1995
Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone, 1995, Volume: 16, Issue:2 Topics: Animals; Biomarkers; Bone Density; Bone Development; Bone Resorption; Calcitonin; Disease Models, An	1995
Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1994, Volume: 9, Issue:2 Topics: Adenocarcinoma; Analysis of Variance; Animals; Body Weight; Bone and Bones; Bone Neoplasms; Bone Res	1994
Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. The Journal of clinical endocrinology and metabolism, 1993, Volume: 77, Issue:4 Topics: Administration, Oral; Aged; Alkaline Phosphatase; Analysis of Variance; Bone Resorption; Calcium; Et	1993
Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:11 Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Disease Models, Animal	1995
TRK-530 inhibits accumulation of superoxide anions derived from human polymorphonuclear leukocytes and bone resorption induced by activated osteoclasts. Pharmacology, 1998, Volume: 56, Issue:3 Topics: Animals; Animals, Suckling; Antioxidants; Bone Resorption; Calcitriol; Calcium Channel Blockers; Dip	1998
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1998, Volume: 13, Issue:4 Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; E	1998
Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone, 1998, Volume: 23, Issue:1 Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Calcium Cha	1998
Risedronate for Paget's disease of bone. The Medical letter on drugs and therapeutics, 1998, Aug-28, Volume: 40, Issue:1034 Topics: Administration, Oral; Aged; Bone Resorption; Calcium Channel Blockers; Clinical Trials as Topic; Dia	1998
Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Digestive diseases and sciences, 1998, Volume: 43, Issue:9 Topics: Alendronate; Animals; Bone Resorption; Diphosphonates; Dogs; Esophagus; Etidronic Acid; Mucous Membr	1998
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone, 1998, Volume: 23, Issue:5 Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcium; Culture	1998
Skeletal effects of constant and terminated use of sodium risedronate in ovariectomized rats. Zhongguo yao li xue bao = Acta pharmacologica Sinica, 1998, Volume: 19, Issue:2 Topics: Animals; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Osteoporosis, Po	1998
The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:5 Topics: Alendronate; Alkyl and Aryl Transferases; Amino Acid Sequence; Animals; Base Sequence; Bone Resorpti	2000
Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. Journal of dental research, 2000, Volume: 79, Issue:6 Topics: Analysis of Variance; Animals; Bone Resorption; Calcitonin; Calcium Channel Blockers; Diphosphonates	2000
Drugs for prevention and treatment of postmenopausal osteoporosis. The Medical letter on drugs and therapeutics, 2000, Oct-16, Volume: 42, Issue:1090 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton	2000
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology, 2000, Volume: 141, Issue:12 Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Bone Resorption; Diphosphonates; Enzyme Inhibitor	2000
Once-a-week alendronate (Fosamax). The Medical letter on drugs and therapeutics, 2001, Mar-19, Volume: 43, Issue:1100 Topics: Alendronate; Bone Resorption; Calcium Channel Blockers; Chemistry, Pharmaceutical; Clinical Trials a	2001
[Fluorides and bisphosphonates in the treatment of osteoporosis]. Der Orthopade, 2001, Volume: 30, Issue:7 Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Dru	2001
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone, 2001, Volume: 29, Issue:6 Topics: Actins; Alendronate; Animals; Apoptosis; Bone Resorption; Cytoskeleton; Etidronic Acid; Mice; Osteoc	2001
Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology, 2002, Volume: 143, Issue:7 Topics: Aging; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Ca	2002
Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1992, Volume: 7, Issue:9 Topics: Aging; Animals; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption	1992
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1991, Volume: 6, Issue:9 Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic	1991

risedronic acid and Bone Loss, Osteoclastic